Treatment of SARS-CoV-2 Relapse with Remdesivir and Neutralizing Antibodies Cocktail in a Patient with X-Linked Agammaglobulinemia
During the Coronavirus Disease 2019 pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having negative outcome. Little data are available on therapeutic options for this population. We discuss the treatment of SARS-CoV-2 relapse with remdesivir and monoclonal antibodies in an adult patient with X-Linked Agammaglobulinemia.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Emanuele Palomba, Maria Carrabba, Gianluca Zuglian, Laura Alagna, Paola Saltini, Valeria Fortina, Cinzia Hu, Alessandra Bandera, Giovanna Fabio, Andrea Gori, Antonio Muscatello Tags: Case Report Source Type: research
More News: Coronavirus | COVID-19 | Infectious Diseases | Pandemics | SARS | X-Linked Agammaglobulinemia (XLA)